There are currentlyn od rugs availablef or the treatment of enterovirus (EV)-induceda cute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we reportt he discovery and characterization of pyrazolopyrimidines,awell-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of ab road spectrum of EV in vitro with IC 50 values between 0.04 and 0.64 mm for viruses resistant to pleconaril,aknown capsidbindingi nhibitor,w ithout affecting cytochrome P450 enzyme activity.U sing virological and genetics methods, the viral capsid was identified ast he target of the most promising, orally bioavailable compound 3-(4-trifluoromethylphenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine (OBR-5-340).I ts prophylactic as well as therapeutic applicationw as proved for coxsackievirus B3-induced chronic myocarditis in mice. The favorablep harmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR-5-340 ahighly promising drug candidate,a nd the regulatory nonclinical program is ongoing.
Vadim A. Makarov, [b] HeikeB raun, [a] Martina Richter, [a] Olga B. Riabova, [b] Johannes Kirchmair, [c] ElenaS.K azakova, [b] Nora Seidel, [a] Peter Wutzler, [a] and Michaela Schmidtke* [a] There are currentlyn od rugs availablef or the treatment of enterovirus (EV)-induceda cute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we reportt he discovery and characterization of pyrazolopyrimidines,awell-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of ab road spectrum of EV in vitro with IC 50 values between 0.04 and 0.64 mm for viruses resistant to pleconaril,aknown capsidbindingi nhibitor,w ithout affecting cytochrome P450 enzyme activity.U sing virological and genetics methods, the viral capsid was identified ast he target of the most promising, orally bioavailable compound 3-(4-trifluoromethylphenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine (OBR-5-340).I ts prophylactic as well as therapeutic applicationw as proved for coxsackievirus B3-induced chronic myocarditis in mice. The favorablep harmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR-5-340 ahighly promising drug candidate,a nd the regulatory nonclinical program is ongoing.
The genus enterovirus (EV) of the family picornaviridae includes more than 100 rhinovirus (RV) serotypes and about 70 EV serotypes, each of them classified into speciesA -D. [1] These viruses are capableo fc ausing aw ide range of acute and chronic diseases.
[2] Each year,m illions of peoples uffer from the common cold, asthma, chronic obstructive pulmonary disease exacerbation, otitis or pneumonia after infection with rhinoviruses. [2b] EVs such as echoviruses 9, 11,3 0( ECHO-9, -11, and -30) and coxsackieviruses B1-6 (CVB1-6) can cause severe conditions, including aseptic meningitis, encephalitis, and acute and chronic myocarditis with or without consecutive dilatedc ardiomyopathy. [2a] Broad-spectrum anti-enteroviral drugs are urgently needed, but despite intensive research no specific drugs have been approvedf or the treatment of EV infections so far.
[3] Drug candidates include the RNA synthesis inhibitor enviroxime and the protease 2C inhibitor AG 7088. [3a, b] Pleconaril, ac apsid inhibitor with broad-spectrum activity against EVs, [4] failed approval by the US Food and Drug Administration for the oral treatment of the commonc old due to al ack of efficacy and safetyc oncerns relatedtothe induction of certain cytochrome P450 enzymes. [5] Results from ap hase II clinical trial (NCT00394914) with an intranasal formulation of pleconaril have yet to be published. [6] 1,2-Benzisoxazoles represent as econd class of potential capsid inhibitors, with drug candidate vapendavir currently under development.
[7] Its binding mode and activity spectrum closely resemble those of pleconaril, [4a, b, 7-8] which may be af actor in the observed cross-resistance with pleconaril. [7b] High-level resistance to capsid inhibitors resultingf rom single amino acid substitution of residues forming the hydrophobic inhibitor binding pocket of viral capsid protein 1( VP1) have been observed. [9] It has been suggested that substituted amino acids block the integration of the inhibitors into the pore. Such single amino acids ubstitutions in VP1 were also shown to confer high-level pleconaril resistance to EVs, [4a, c, 8, 10] whereby I1092L substitution, situated in proximity of the central, methylated phenoxy group of pleconaril in VP1, was most commonly observed for CVB3.
[ activity and showed that selected ring decorations can break drug resistance. [11] These and further considerations led to the exploration of as eries of pyrazolo[3,4-d]pyrimidines as novel drug candidates fort he treatment of EV infections (Scheme 1; see also, Table S1 in the Supporting Information). [12] Herein, we report their synthesis, physicochemicalc haracteristics, structure-activity relationshipsa nd unique anti-enteroviral activities.
All synthesized compounds (~80, plus pleconaril as ar eference) were initially subjected to cytotoxicity (see the Supporting Information) and antiviral testing (inhibition of the cytopathic effect, CPE) in HeLa cell cultures. Most of them were wellt olerated (Table S2 in the Supporting Information). Analogues derived from a3 -phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine scaffold were particularly promising, exhibiting strong activity againstC VB3, RV2,5 ,8 ,4 2, and 48 (RV5, RV42, andR V48 are known [4a] and confirmed by our data as high-level pleconaril-resistant;a ctivity measureda sd escribed in Table S2 in the Supporting Information). Amino groups at positions 3a nd 4o f the central ring are critical for antiviral activity.D ifferent substitutionso ft he aniline are possible. Most active compounds comprisea tl east one halogen or trifluoromethyl group (e.g., compounds 24, 25, 32, 36,and 41).
Compound 36 (MW: 370.3;l og P = 2.85;S cheme 1) showed particularly favorable physicochemical, antiviral, and pharmacokinetic properties ( Figure 1a nd Ta ble1;s ee also, Ta bles S2 and S4 in the Supporting Information). It was synthesized in four steps with high yield, [12b] as summarized in Scheme 1. Compound 25,a na naloguew itha4-fluoroaniline moiety, was also highly active in vitro but almost inactive in vivo (results not shown). The compound is hydroxylated in vivo to form the 100-to 5000-fold weaker metabolite 15.T his renders 25 unsuitablef or oral administration. By introducing an electron-withdrawing trifluoromethyl group into 36,i ts pharmacokinetica nd metabolic properties were improved (Tables S4  and S5 in the Supporting Information).
Scheme1.Synthetic route to compound 36. [12] Reagents and conditions: a) toluene, reflux, 3h,95%;b )NaH, CH 2 (CN) 2 ,DMF,2 08C, 5h,9 5%; c) NH 2 NH 2 H 2 O, EtOH, reflux, 2.5 h, 67 %; d) PhC(NH)NH2, NaAc, butanol, melt at 170-180 8C, 25 min,2 5%. Figure 1A ;s ee also the Supporting Information).
We postulate that inhibitor bindingt ov iral capsid proteins leads to the prevention of virus adsorption and might also be responsible for the observed antiviral effect during and after adsorption.T he detection of amino acid substitutions in VP1 (2 P1094S, 2S1190T,1 I1207N, 1I1207M) andV P2 (2 S2209C)o fh igh-level 36-resistant CVB3 Nancy variants supports this (Table 1 ). In agreement with pleconaril studies, [8] ac oncentration of 1 mgmL À1 (2.7 mm)o f36 wasu sed for their isolation.I nt en independently prepared pools of wild-type CVB3 Nancy,t he mean frequency of resistance to 36 was~7 10 5 ,c orresponding well with the data published for pleconaril. [8] Based on these phenotypic and genotypic data, we expect that the lipophilic 36 binds inside the hydrophobic pocket of VP1 in as imilarf ashion to pleconaril and vapendavir.
[7b, 15] The potentialb inding mode of 36 as derived by automated ligand dockingw ith GOLD [16] corroborates this mechanism of action ( Figure 2B,C) . The models uggeststhat the observed mutations causing high-level resistance induce larger conformational rearrangements leadingt ot he disruption of hydrophobic interactions formed by the trifluorophenyl moiety of 36 (which is postulated to correspond to the methylisoxazole moiety in pleconaril).
Ap anel of 46 RV serotypes comprising viruses from species A( n = 33) and B( n = 13), two EV species A, nine EV species B, one EV species C, and two EV speciesD were assessed regarding their sensitivity to 36 in CPE inhibition assays in HeLa cells. [13] Compound 36 inhibited 52 of the 60 strains tested ( Figure 1B ). Stronga ntiviral activity was detected against ECHO11a nd EV68, which are known to causeo utbreaks of aseptic meningitis and acute lower respiratoryt ract infections, respectively.
[14] The highest activities were measured against high-level pleconaril-resistant viruses including RV5, RV42, RV44, RV48, and RV69.
[4a, c, 10] The IC 50 values for these specific EVs ranged from 0.04 to 0.64 mm (Table S2 in the Supporting Information).
The effect of 0.5 and 1 mm of 36 on different steps of the viral replication cycle was studied in plaque reduction assays with CVB3 Nancy in HeLa cells (Figure 2A) . Pretreatment of cells with 36 prior to virus inoculation had no effect on virusinduced plaque formation.I nc ontrast, incubation of 36 with cell-free virus resulted in strongl oss of virus infectivity as shownb yh igh percentage of plaque reduction in Figure 2A . Here, high concentrations of CVB3 Nancy werei ncubated with or withoutt he inhibitor in test medium for one hour at 37 8C. Then the mixture wasd iluted 1:10
6 to obtain noneffective inhibitor concentrationsa nd added to confluentc ell monolayers for virus adsorption.
Acute (> 3gkg
À1
)a nd chronic (12.5, 50 and 200 mg kg À1 doses, 30 days treatment in male BALB/c mice) toxicological studies in mice showed no indications of adversea natomical, behavioral or physiological effects (see Table S3 in the Supporting Information). In vitro ADMET profiling of 36 (Table S4 in the Supporting Information) included analysis of plasma protein binding and recovery( 96.7 %a nd 100 %, respectively), plasma stability( 100 %), mutagenicity (none), and hERG channel inhibition (low). Compound 36 is neither an inducer nor an inhibitor of relevant cytochromeP 450 isoforms. A1 00 %m etabolic stability of 36 in human liver microsomes was observed (see the Supporting Information, Table S4 ) explaining in vitro its efficacy after oral administration in mice. The in vitro data were confirmed by pharmacokinetics studies in miced uring a1 00 mg kg À1 per os administration. The in vivo results show that 36 has druglike pharmacokinetic properties, as reported in the Supporting Information (Table S5) . Effective compound concentrations were reached by oral administration of 100 mg kg À1 of 36 twice daily,f or 7days. When treatment was started3hp rior to (prophylactically) or 1a nd 3 days p. i. (therapeutically), 36 exerted as trong antiviral effect in am odel of CVB3-induced chronic myocarditis in NMRI mice (Figure 3 ; see also, Ta bles S6 and S7 in the SupportingI nformation). Placebo-treated, CVB3-infected mice markedly lost body weight( Figure3A) and becamei ll ( Figure 3B )o nd ay 3p .i. Prophylactic and therapeutic treatment significantly improved both study parameters (Figure 3) . As ar esult of viral replication, pronounced inflammation as well as necrosis and fibrosis of myocardial tissue were observed in hematoxylin-eosina nd sirius red-stained heart specimens,r espectively,i np lacebotreated animalso nd ay 28 p. i. (Figure 3C ). CVB3 also completely destroyed the exocrine pancreas tissue (Figure3C). Compound 36 significantly decreased tissue damage as wella s inflammation in the heart andp ancreas when treatment was started 3h before,o r1or 3d ays p. i. No therapeutic effect was observed when treatment started 7d ays p. i. (results not shown).
In conclusion, pyrazolopyrimidines represent an ovel class of compounds targeting the capsid of clinical important RVsa nd EVs. Notably,l ead compound 36 is orally available, inhibits ab road-spectrum of EVs and RVs, helps to overcome the resistanceo fk nown capsid inhibitors, and does not exerta n effect on relevant cytochrome isoforms.T he favorable pharma- 
Experimental Section
Chemistry:T he synthesis of compound 36 as shown in Scheme 1 is described in detail in the Supporting Information together with synthetic protocols for access to control compounds (guanidine hydrochloride and pleconaril).
Computational methods:I nformation on the homology model used to predict the binding mode and ligand docking methods is also given in the Supporting Information.
In vitro assays:A lso presented in the Supporting Information are details of the in vitro studies performed, including analysis of cytotoxicity and antiviral activity (CPE inhibition assay) of pyrazolopyrimidines in HeLa cells, mechanism of action studies (modified plaque-reduction assay), isolation [8] and phenotypic (plaque-reduction assay), as well as genetic characterization of 36-resistant variants. Information on the cells, virus strains, growth conditions, and virus titer determination are also described.
In vivo models:T he in vivo studies on the prophylactic and therapeutic antiviral effect, the pharmacokinetic, and the toxicity of 36 were performed in mice. The experimental design was reviewed and approved by local government (ThüringerLandesamt für Lebensmittelsicherheit und Verbraucherschutz);t he registration number is 02-001/07 (antiviral studies), and by the State Scientific Center for Antibiotics, Moscow; the registration number is 267/ 2010 (pharmacokinetic and toxicity). For details, see the Supporting Information. www.chemmedchem.org
